Exelixis, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| EXEL | SMMT | RCUS | ERAS | GMAB | IDYA | |
|---|---|---|---|---|---|---|
| Market cap | 14.82B | 13.67B | 3.06B | 5.41B | 22.98B | 3.48B |
| P/E (TTM) | 18.9 | — | — | — | 29.4 | — |
| Forward P/E | 14.0 | -15.0 | -7.5 | -24.8 | 24.5 | -9.0 |
| Price/book | 8.1 | 21.6 | 6.7 | 13.4 | 3.7 | 2.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +55.72% | −23.29% | +46.69% | +567.92% | +13.43% | +34.89% |
| Today | −0.07% | −2.62% | −0.29% | −3.56% | +0.81% | −0.14% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All EXEL news ›Bank of America Securities Sticks to Its Sell Rating for Exelixis (EXEL)
In a report released today, Jason Gerberry from Bank of America Securities maintained a Sell rating on Exelixis, with a price target of $41.00. According to TipRanks, Gerberry is a 5-star analyst with an average return of 18.5% and a…
FDA Extends Review of Exelixis' Zanzalintinib in Colorectal Cancer
Published on 09/11/2026 at 07:51 am EDT Exelixis said the Food and Drug Administration has extended its review of the company's proposed zanzalintinib cancer drug by three months. Exelixis, which is seeking FDA approval zanzalintinib in…
Exelixis (NASDAQ:EXEL) Stock Gets Price Target Cut from Royal Bank Of Canada
Posted by Tristan Rich on Oct 11th, 2026 Exelixis (NASDAQ:EXEL – Free Report) had its price target trimmed by Royal Bank Of Canada from $46.00 to $45.00 in a report issued on Thursday morning, MarketBeat reports. The brokerage currently…
Metastatic Castration Resistant Prostate Cancer Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Telix Pharma, Merck, Orion Pharma, Exelixis
Metastatic Castration Resistant Prostate Cancer Pipeline openPR.com Metastatic Castration Resistant Prostate Cancer Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Telix Pharma,…
Exelixis Inc. Common Stock (EXEL) Stock Price Today
EXEL Stock Fundamentals & Key Ratios Pluang Track Exelixis Inc. Common Stock (EXEL) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Exelixis Inc. Common Stock has traded between a…
RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating
Exelixis has an average rating of overweight and mean price target of $54.87, according to analysts polled by FactSet. ... Biotechnology & Medical Research RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating…
Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says
Exelixis' clinical trials evaluating Zanzalintinib in various types of cancer are highly likely to succeed, RBC Capital Markets analysts said in a Friday note. Analysts said that indications of... Biotechnology & Medical Research Exelixis'…
Is Exelixis Stock Engineered To Make You Money?
Exelixis (EXEL) stock has returned 46% over the past twelve months, compared with 17.8% for the S&P 500. The company has aggressively repurchased its own stock, reducing its total share count by 21% over the last three years. Because fewer…
US FDA extends review of Exelixis' cancer drug
The U.S. Food and Drug Administration has extended the review of Exelixis' experimental colorectal cancer drug combination by three months, the company said in a filing on Friday. The... Biotechnology & Medical Research US FDA extends…
Owning the Improvement Is Not Freedom to Operate: Exelixis v. MSN Shows the Reach of Earlier Genus Patents
Exelixis holds the New Drug Application for Cabometyx, a cancer treatment containing cabozantinib (L)-malate. During development, Exelixis investigated different solid-state forms of the compound and identified two crystalline polymorphs…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com3
-
themarketsdaily.com2
-
opi.net1
-
pluang.com1
-
theglobeandmail.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 11 articles, not a forecast.